PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers

Vonoprazan (VPZ), an oral potassium-competitive acid blocker (P-CAB) has emerged as an alternative potent acid-suppressant.It has a faster onset of action in 1 day (3-5 days in PPI), and is more stable in acidic condition than PPI. While many studies compared Vonoprazan against PPI in the treatment of reflux oesophagitis, H. Pylori eradication, and gastric ulcers; thus far, there is a paucity of data on use of Vonoprazan on bleeding peptic ulcers. We perform a multicenter randomized controlled trial (RCT) to compare the efficacy of oral Vonoprazan against standard high dose PPI therapy in bleeding peptic ulcers that had received successful endoscopic haemostasis We hypothesize that in patients with bleeding peptic ulcers, the use of acid pump inhibitors Vonoprazan would not be inferior to standard treatment of a bolus plus high dose PPI intravenous infusion at preventing recurrent bleeding after endoscopic haemostasis.

NCT Number	NCT05582174
Lead Sponsor	Chinese University of Hong Kong Collaborators: Nanfang Hospital, Southern Medical University
Conditions	Upper GI Bleeding, Proton Pump Inhibitors
Enrollment	594 participants
Start Date	2023-05-18
Primary Completion	2028-01-02 (estimated)
Study Completion	2028-07-03 (estimated)
Updated on ClinicalTrials.gov	2026-03-18